Chabiotech's business spans four areas: global healthcare, domestic profit businesses, cell and gene therapy (CGT) development and contract manufacturing (CDMO), and AI-based digital healthcare.
Overseas medical services are the largest contributor, with the company operating medical institutions and providing fertility and reproductive medicine services in the United States, Singapore and Australia.
In the third quarter of 2026, hospital revenue was KRW 177.2 billion, the bulk of consolidated revenue of KRW 255.5 billion, and it fell 6.8% from a year earlier.
Product sales rose 10.5% to KRW 12.3 billion and service revenue rose 14.9% to KRW 31.4 billion, while goods sales fell 22% to KRW 26.1 billion and other-income revenue dropped 85.1% to KRW 8.5 billion.
On a standalone basis, BI, IT and cord blood businesses drove cumulative nine-month revenue of KRW 48.9 billion, up 8% year on year.
In CGT, the U.S. subsidiary Matica Biotechnology has expanded contracts with local biotech companies and is pursuing new clients through a K-FIH program that links U.S. manufacturing with Korean clinical capacity.
Key pipeline assets include CHAGE-201 for idiopathic pulmonary fibrosis, the NK cell therapy CBT101 for solid tumors, CBT210-POI for premature ovarian insufficiency, and PlaSTEM-AD for Alzheimer's disease.
In CDMO, the company is compared with large contract manufacturers such as Samsung Biologics, while its bispecific antibody efforts overlap with antibody-focused peers such as ABL Bio.